171 results about "Liver disorder" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention belongs to the technical field of hepatopathy treatment drugs, and particularly relates to an anti-inflammatory and anti-oxidative stress nano-enzyme Cu5.4O atCNDs with cascade enzyme activity and application of the nano-enzyme Cu5.4O atCNDs. The nano-enzyme Cu5.4O-coated CNDs is prepared by the following steps: dissolving CuCl2 in a carbon dot aqueous solution, reacting for 10-12 minutes at the temperature of 75-80 DEG C, then adding an L-ascorbic acid aqueous solution, regulating the pH value to 7.0-8.0 by using a NaOH solution, reacting for 10-12 hours at the temperature of 75-80 DEG C, after the reaction is finished, centrifuging to remove precipitates, dialyzing supernate, and freeze-drying to obtain the Cu5.4O-coated CNDs. Research results of the invention prove that the nano-enzyme Cu5.4O-coated CNDs has the potential of treating various acute liver injury diseases, and is an intervention strategy with a good clinical application prospect.

The present disclosure provides a method of treating or preventing a liver disorder (e.g., NASH) in a subject with a THR-β agonist, using a biomarker test (e.g., to determine a dose of the THR-β agonist).

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

The present disclosure is directed to oral dosage forms of TRβ agonist VK2809 and methods of preparing the same. The disclosure provides oral dosage forms of VK2809 with improved stability and solubility properties that allow for storage under normal conditions through the use of spray-drying with one or more polymers selected from the group consisting of: polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidinone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyethylene oxide) (PEO), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), copovidone, poloxamer 407, hypromellose acetate succinate (HPMCAS), polyacrylates and combinations thereof.

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.

The invention discloses a long-term prognosis prediction system and method for patients with liver diseases, and the method comprises the following steps: S1, collecting clinical data, including anthropometric data, vital signs, laboratory data and albumin binding capacity obtained by specific detection, of patients with acute decompensation of liver cirrhosis and chronic plus acute liver failure; s2, a competitive risk model for predicting death of patients suffering from acute decompensation of liver cirrhosis and chronic and acute hepatic failure after admission for one year is constructed, the prediction model is constructed by adopting the competitive risk model, and a convenient prediction tool is made by adopting a dynamic column diagram visual prediction model; and S3, evaluating the prediction performance of the model through the working curve of the subject. According to the present invention, the index relationship between the albumin binding capacity and the long-term prognosis of the decompensated liver cirrhosis patient and the chronic plus acute liver failure patient is established so as to provide the important clinical significance, such that the clinical management can be further optimized, and the drug treatment can be guided.

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).

The present invention relates to classification of liver lesions by a liver ultrasound image and, more specifically, to an artificial intelligence model for classifying liver lesions by using a liver ultrasound image, a method for constructing the model, and a method for classifying liver lesions by using the artificial intelligence model. To this end, the present invention provides a method for constructing an artificial intelligence model for classifying liver lesions by using a liver ultrasound image, the method comprising: a preparation step of excluding an image corresponding to a predetermined exclusion criterion, among a plurality of liver ultrasound images (S100); a step, executed by a computer, of receiving by the computer, the plurality of prepared liver ultrasound images as original images (S120); a step of cross-allocating the original images to a plurality of folds according to liver lesions (S140); a step of image-processing each original image for training (S160); and a step of training an artificial intelligence model by using the image-processed image (S180).

The invention discloses an extraction method of American ginseng glycoprotein, an obtained product and application, American ginseng is used as a main raw material, a natural eutectic solvent aqueous solution is used as a solvent, warm immersion stirring, ultrasonic and microwave extraction are performed in sequence to obtain an extracting solution, then the extracting solution is subjected to subsequent operations such as alcohol precipitation and free protein removal, and the American ginseng glycoprotein is obtained. The American ginseng glycoprotein is obtained. The American ginseng glycoprotein extraction method is simple in process, high in safety, high in yield and purity and suitable for industrial production, and the obtained American ginseng glycoprotein has liver protection / liver protection and antioxidant activity, can be prepared into drugs, health care products and food, provides clinical guidance and medication basis for patients with liver diseases, further improves the life quality of the patients and has a good clinical application prospect. And the method has good application value.

Provided are an inhibitor containing a bicyclic derivative, a preparation method therefor and the use thereof. In particular, involved are a compound shown by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an RET inhibitor in the treatment of cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases, AIDS, and other related diseases, wherein each substituent in general formula (I) has the same definition as that given in the description.

Provided herein are novel 2,4-dinitrophenol (DNP) derivatives and prodrugs of formula (I), as modulators of mitochondria functions, as well as pharmaceutical compositions comprising a compound described above and methods thereof for treating various diseases and disorders associated with or related to mitochondrial dysfunctions (e.g., obesity, diabetes, insulin resistance, liver diseases, heart or renal failure, neurodegenerative diseases or aging related diseases).

Featured are methods of identifying (e.g., diagnosing) and / or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and / or liver cancer (e.g., HCC). The methods utilize predictive and / or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and / or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

The traditional Chinese medicine preparation for treating hepatopathy can be used for treating jaundice hepatitis, chronic hepatitis, alcoholic liver, liver injury, hepatitis B and early cirrhosis with symptoms such as hypochondriac swelling pain, inappetence, hypodynamia and abdominal fullness caused by uncomfortable liver qi and qi stagnation and blood stasis. In the treatment process of the hepatopathy, the action effect of the traditional Chinese medicine is slow and lasting, so that the raw material medicines are all crushed and prepared into the pill, the action time of the medicine is prolonged while the medicine effect is ensured, and the treatment of the hepatopathy is facilitated.

The application discloses a prognosis risk prediction model construction system and method based on chronic disease real world data, comprising a multi-source real world data acquisition and access module, a data standardization and quality control module, a multi-dimensional feature engineering and screening module, a comorbidity feature fusion and data set construction module, a prognosis risk prediction model training and optimization module, a model multi-dimensional verification and evaluation module, a model deployment and risk stratification output module; a special multi-source real world data acquisition and quality control system for chronic liver disease, diabetes and hypertension is constructed, data standardization processing is realized in combination with a chronic disease clinical diagnosis and treatment guideline, through multi-dimensional missing value, abnormal value processing and data deduplication integration, the quality and availability of the real world data are effectively improved, the core problem of disorderly and low-quality real world data in the prior art is solved, and a high-quality data source basis is provided for model construction.

The present invention relates to the technical field of liver disease treatment, and in particular to the use of mesenchymal stem cells in preventing or treating liver disease. The present invention uses miR-3059-5p as a therapeutic target, constructs umbilical cord mesenchymal stem cells transfected with miR-3059-5p, and verifies that the umbilical cord mesenchymal stem cells prepared by the present invention have good liver repair ability and can be used for the treatment of patients with acute liver injury.

The present disclosure is directed to a method of monitoring treatment of metabolic dysfunction-associated steatohepatitis (MASH) in a patient by initiating a treatment by administering Compound 1: (Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient, determining percentage increase in the level of SHBG from baseline, and continuing administration of Compound 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient if the percentage increase in the level of SHBG is at least 50% from baseline.

Small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and their use and preparation are disclosed herein.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize treatment with a THR-β agonist.

The present technology provides crystalline free base and crystalline hydrochloride, hydrobromide, edisylate, and mesylate salts of (R)-2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methyl)-2-methylpiperazin-1-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid. The present technology further provides methods for preparing the various forms, compositions containing them, and methods related to modulation of FXR. In particular, the present crystalline compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., hepatitis B, liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

The invention discloses compounds of Formula (I), wherein the compounds are used as anti-inflammatory agents, for treatment or prevention of a number of diseases or conditions such as atherosclerosis, auto-immune diseases, psoriasis, multiple sclerosis, transplant rejection, asthma, bacterial infection, rhinovirus infection, brain ischemia, ischemia-reperfusion injury, limb ischemia, acute kidney injury, diabetic nephropathy, sepsis, acute respiratory distress syndrome (ARDS), cancer, osteoarthritis, sepsis-induced kidney injury, liver disease, and septic and cardiogenic shock.

The invention relates to the technical field of medical auxiliary instruments, and discloses an abdominal puncture auxiliary device for the hepatopathy department, the abdominal puncture auxiliary device comprises a supporting plate main body, the top of the supporting plate main body is slidably connected with a trunk fixing structure. According to the abdominal puncture auxiliary device for the hepatopathy department, a movable plate slidably connected to the top of the supporting plate body is matched with a limiting block and a threaded rod with a handle, so that a trunk is rapidly clamped by a first clamping plate, and the left-right position of the trunk is adjusted; a clamping block is driven by a buckle shell with a first spring and a pull rod to be connected with a plurality of clamping grooves in a supporting plate body in a clamped mode, accurate adjustment and locking of the overall position of the trunk fixing structure are achieved, and a multi-degree-of-freedom connecting rod mechanism is formed by sequentially hinging a first connecting rod, a second connecting rod and a third connecting rod and provided with a resistance pad at the hinged position; flexible hovering and positioning of the limbs of the patient are achieved, and automatic adaptation and elastic clamping of the upper limbs of the patient are achieved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

To provide methods and systems for assays that accurately determine lipoproteins in a plasma or serum sample and predict patient mortality, in contrast to conventional lipid panels incapable of detecting the presence of LP-X or LP-Z.SOLUTION: Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy, and more specifically, methods for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.SELECTED DRAWING: Figure 4

This document describes bile acid derivatives, their manufacturing methods, and their uses. These derivatives have shown potential as therapeutic agents for the treatment of liver diseases.